Pneumonia (Cryptococcus neoformans)

Overview

Plain-Language Overview

Pneumonia caused by Cryptococcus neoformans is a lung infection that primarily affects the respiratory system. This condition occurs when the fungus Cryptococcus neoformans enters the lungs, leading to inflammation and difficulty breathing. People with weakened immune systems are more likely to develop this infection. Common symptoms include cough, fever, and chest pain. The infection can sometimes spread beyond the lungs, causing more serious health problems. Early detection and diagnosis are important to manage the disease effectively.

Clinical Definition

Pneumonia (Cryptococcus neoformans) is a fungal lung infection caused by inhalation of the encapsulated yeast Cryptococcus neoformans. It primarily affects immunocompromised patients, such as those with HIV/AIDS, organ transplants, or on immunosuppressive therapy. The fungus causes a granulomatous inflammatory response in the lung parenchyma, leading to symptoms like cough, dyspnea, and fever. Radiographically, it may present with nodules, consolidation, or cavitary lesions. The infection is clinically significant due to its potential to disseminate, especially to the central nervous system, causing cryptococcal meningitis. Diagnosis and treatment are critical to prevent morbidity and mortality.

Inciting Event

Inhalation of aerosolized Cryptococcus neoformans spores from environmental sources such as soil or bird droppings.
Exposure to contaminated dust or decayed wood in endemic areas triggers initial infection.
Immunosuppressive therapy initiation can precipitate symptomatic disease from latent infection.

Latency Period

Variable latency from weeks to months between spore inhalation and symptom onset is typical.
Subclinical infection may persist for months to years before clinical pneumonia develops.
Rapid progression can occur in severely immunocompromised hosts within days to weeks.

Diagnostic Delay

Nonspecific respiratory symptoms often mimic bacterial pneumonia, delaying fungal consideration.
Low clinical suspicion in immunocompetent patients leads to missed diagnosis.
Negative routine bacterial cultures can mislead clinicians away from fungal etiology.
Delayed use of fungal-specific diagnostics such as cryptococcal antigen testing prolongs diagnosis.

Patient Population

Immunocompromised adults, especially those with advanced HIV infection, are most commonly affected.
Organ transplant recipients and patients on immunosuppressive drugs represent a significant group.
Middle-aged to older adults are more frequently diagnosed due to cumulative immunosuppression.
Rarely, immunocompetent individuals can develop localized pulmonary cryptococcosis.

Risk Factors

HIV/AIDS with CD4 count <100 cells/mm³ is the strongest risk factor for cryptococcal pneumonia.
Immunosuppressive therapy such as corticosteroids or chemotherapy increases susceptibility.
Organ transplantation recipients are at increased risk due to immunosuppression.
Chronic lung disease may predispose to localized infection.
Exposure to environments contaminated with pigeon droppings increases risk of inhaling spores.

Clinical Presentation

Signs & Symptoms

Subacute onset of cough, often nonproductive
Fever and malaise
Dyspnea and chest discomfort
Weight loss and night sweats in chronic cases
Headache or neurological symptoms if dissemination to CNS occurs

History of Present Illness

Subacute onset of cough, dyspnea, and low-grade fever over days to weeks is common.
Chest pain and hemoptysis may occur with extensive lung involvement.
Progressive fatigue and weight loss can accompany chronic infection.
Neurologic symptoms may develop if dissemination occurs, indicating systemic spread.

Past Medical History

Known HIV infection or AIDS diagnosis with low CD4 counts is highly relevant.
History of organ transplantation or immunosuppressive medication use increases risk.
Chronic pulmonary diseases such as COPD or sarcoidosis may predispose to infection.
Previous exposure to environments with bird droppings or decayed wood is important.

Family History

[]

Physical Exam Findings

Crackles or rales on lung auscultation indicating alveolar involvement
Dullness to percussion over areas of consolidation
Tachypnea reflecting respiratory distress
Hypoxemia signs such as cyanosis in severe cases
Fever and signs of systemic infection

Diagnostic Workup

Diagnostic Criteria

Diagnosis is established by identifying Cryptococcus neoformans in respiratory specimens via India ink staining or fungal culture. Detection of cryptococcal antigen (CrAg) in serum or bronchoalveolar lavage fluid supports the diagnosis. Chest imaging typically shows nodular infiltrates or consolidation. Definitive diagnosis requires isolation of the organism or positive antigen testing combined with compatible clinical and radiographic findings.

Pathophysiology

Key Mechanisms

Inhalation of airborne Cryptococcus neoformans spores leads to pulmonary infection.
Polysaccharide capsule of C. neoformans inhibits phagocytosis and immune clearance.
Granulomatous inflammation develops in lung tissue as a host immune response.
Dissemination via bloodstream can occur, especially to the central nervous system.
Impaired cell-mediated immunity allows unchecked fungal proliferation and tissue damage.

Involvement	Details
Organs	Lungs serve as the initial site of Cryptococcus neoformans inhalation and infection
Organs	Central nervous system is a common site of dissemination leading to life-threatening meningitis
Tissues	Pulmonary alveolar tissue is the primary site of infection and inflammation in cryptococcal pneumonia
Tissues	Meningeal tissue may be involved if infection disseminates causing cryptococcal meningitis
Cells	Alveolar macrophages phagocytose Cryptococcus neoformans and initiate immune response
	T lymphocytes mediate cell-mediated immunity critical for fungal clearance
	Neutrophils contribute to fungal killing during acute infection
Chemical Mediators	Interferon-gamma enhances macrophage fungicidal activity against Cryptococcus neoformans
	Tumor necrosis factor-alpha promotes granuloma formation and fungal containment
	Interleukin-12 stimulates Th1 immune response important for fungal control

Treatments

Pharmacological Treatments

Amphotericin B
- Mechanism:
  - Binds ergosterol in fungal cell membranes causing increased permeability and cell death
- Side effects:
  - Nephrotoxicity
  - Infusion-related reactions
  - Electrolyte imbalances
- Clinical role:
  - First-line
Flucytosine
- Mechanism:
  - Inhibits fungal DNA and RNA synthesis by conversion to 5-fluorouracil inside fungal cells
- Side effects:
  - Bone marrow suppression
  - Gastrointestinal upset
  - Hepatotoxicity
- Clinical role:
  - Adjunctive
Fluconazole
- Mechanism:
  - Inhibits fungal cytochrome P450 enzyme 14-alpha-demethylase, impairing ergosterol synthesis
- Side effects:
  - Hepatotoxicity
  - QT prolongation
  - Drug interactions
- Clinical role:
  - Consolidation and maintenance therapy

Non-pharmacological Treatments

Supportive care including oxygen therapy for hypoxemia
Management of increased intracranial pressure if cryptococcal meningitis develops
Removal or reduction of immunosuppressive agents when possible

Prevention

Pharmacological Prevention

Fluconazole prophylaxis in high-risk immunocompromised patients
Antiretroviral therapy to restore immunity in HIV/AIDS
Preemptive antifungal treatment guided by cryptococcal antigen screening

Non-pharmacological Prevention

Avoidance of exposure to bird droppings and contaminated soil
Use of protective masks in high-risk environments
Regular screening for cryptococcal antigen in severely immunocompromised patients
Minimizing immunosuppressive therapy when possible
Prompt treatment of underlying immunodeficiency

Outcome & Complications

Complications

Cryptococcal meningitis from CNS dissemination
Respiratory failure due to extensive pulmonary involvement
Pulmonary fibrosis from chronic inflammation
Disseminated cryptococcosis affecting skin, bones, or other organs
Hydrocephalus secondary to cryptococcal meningitis

Short-term Sequelae	Long-term Sequelae
Hypoxemia requiring supplemental oxygen Pleural effusion development Acute respiratory distress syndrome (ARDS) in severe cases Sepsis from systemic fungal spread Hospitalization for antifungal therapy and supportive care	Pulmonary fibrosis leading to chronic respiratory insufficiency Neurological deficits from cryptococcal meningitis Chronic cough or bronchiectasis post-infection Relapse of infection if immunosuppression persists Reduced pulmonary function due to scarring

Differential Diagnoses

Pneumonia (Cryptococcus neoformans) versus Pneumocystis jirovecii pneumonia

Pneumonia (Cryptococcus neoformans)	Pneumocystis jirovecii pneumonia
Often affects patients with immunosuppression including corticosteroids or organ transplant, but can occur with broader immune defects	Commonly occurs in patients with CD4+ T cell counts <200/μL, especially HIV/AIDS
Caused by encapsulated yeast Cryptococcus neoformans	Caused by the fungal organism Pneumocystis jirovecii
Diagnosis confirmed by India ink stain or cryptococcal antigen in serum or CSF	Diagnosis confirmed by silver stain or immunofluorescence of bronchoalveolar lavage showing cysts
Nodular or mass-like pulmonary lesions, sometimes with cavitation	Diffuse bilateral ground-glass opacities on chest CT

Pneumonia (Cryptococcus neoformans) versus Tuberculosis (Mycobacterium tuberculosis)

Pneumonia (Cryptococcus neoformans)	Tuberculosis (Mycobacterium tuberculosis)
Caused by encapsulated yeast Cryptococcus neoformans	Caused by acid-fast bacillus Mycobacterium tuberculosis
Pulmonary nodules or masses with noncaseating granulomas or gelatinous mucoid material	Upper lobe cavitary lesions with caseating granulomas
Positive cryptococcal antigen test and yeast on India ink stain	Positive acid-fast bacilli stain and culture
May present subacutely with respiratory symptoms and possible dissemination	Chronic, slowly progressive respiratory symptoms with systemic signs like night sweats

Pneumonia (Cryptococcus neoformans) versus Histoplasmosis

Pneumonia (Cryptococcus neoformans)	Histoplasmosis
Exposure to soil contaminated with pigeon droppings or decaying wood worldwide	Exposure to bird or bat droppings in endemic areas such as Ohio and Mississippi River valleys
Caused by encapsulated yeast Cryptococcus neoformans	Caused by dimorphic fungus Histoplasma capsulatum
Pulmonary nodules or masses, sometimes with cavitation	Mediastinal or hilar lymphadenopathy with patchy infiltrates
Positive cryptococcal antigen test and yeast on India ink stain	Positive urine or serum Histoplasma antigen test

Pneumonia (Cryptococcus neoformans) versus Bacterial pneumonia (e.g., Staphylococcus aureus)

Pneumonia (Cryptococcus neoformans)	Bacterial pneumonia (e.g., Staphylococcus aureus)
Caused by encapsulated yeast Cryptococcus neoformans	Caused by bacteria such as Staphylococcus aureus or Streptococcus pneumoniae
Subacute or chronic onset with dry cough and less purulent sputum	Acute onset with high fever, productive cough, and purulent sputum
Nodular or mass-like lesions, sometimes cavitary	Lobar consolidation or abscess formation
Requires antifungal therapy such as amphotericin B or fluconazole	Rapid improvement with appropriate antibacterial therapy